Antares Pharma (ATRS) 10-Q 2 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 30, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Trading Symbol	ATRS
Entity Registrant Name	ANTARES PHARMA, INC.
Entity Central Index Key	0001016169
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		162,619,811

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 23,238	$ 27,892
Accounts receivable	29,772	18,976
Inventories	13,378	11,350
Contract assets	9,445	10,442
Prepaid expenses and other current assets	3,657	2,648
Total current assets	79,490	71,308
Equipment, molds, furniture and fixtures, net	15,100	14,895
Right-of-use assets	1,910
Intangibles, net	688	831
Goodwill	1,095	1,095
Other assets	502	148
Total Assets	98,785	88,277
Current Liabilities:
Accounts payable	15,622	11,135
Accrued expenses and other liabilities	11,844	11,997
Long-term debt, current portion	4,933	3,043
Lease liabilities, current portion	866
Deferred revenue	1,537	1,018
Total current liabilities	34,802	27,193
Long-term debt	20,260	22,083
Lease liabilities, long-term	1,055
Total liabilities	56,117	49,276
Stockholders’ Equity:
Preferred Stock: $0.01 par, authorized 3,000 shares, none outstanding
Common Stock: $0.01 par; 300,000 shares authorized; 162,528 and 159,721 issued and outstanding at March 31, 2019 and December 31, 2018, respectively	1,625	1,597
Additional paid-in capital	323,972	314,907
Accumulated deficit	(282,223)	(276,800)
Accumulated other comprehensive loss	(706)	(703)
Total Stockholders' Equity	42,668	39,001
Total Liabilities and Stockholders’ Equity	$ 98,785	$ 88,277

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred Stock, par value	$ 0.01	$ 0.01
Preferred Stock, shares authorized	3,000,000	3,000,000
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.01	$ 0.01
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	162,528,000	159,721,000
Common Stock, shares outstanding	162,528,000	159,721,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue:
Total revenue	$ 23,286	$ 12,703
Cost of revenue:
Total cost of revenue	10,946	7,186
Gross profit	12,340	5,517
Operating expenses:
Research and development	2,387	2,900
Selling, general and administrative	14,935	8,236
Total operating expenses	17,322	11,136
Operating loss	(4,982)	(5,619)
Interest expense	(661)	(631)
Other income	104	57
Net loss	$ (5,539)	$ (6,193)
Basic and diluted net loss per common share	$ (0.03)	$ (0.04)
Basic and diluted weighted average common shares outstanding	160,446	156,724
Product sales [Member]
Revenue:
Total revenue	$ 18,300	$ 10,949
Cost of revenue:
Total cost of revenue	10,568	6,536
Licensing and Development Revenue [Member]
Revenue:
Total revenue	915	1,285
Royalties [Member]
Revenue:
Total revenue	4,071	469
Cost of development revenue [Member]
Cost of revenue:
Total cost of revenue	$ 378	$ 650

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (5,539)	$ (6,193)
Foreign currency translation adjustment	(3)	10
Comprehensive loss	$ (5,542)	$ (6,183)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2017	$ 33,547	$ 1,567	$ 302,965	$ (270,285)	$ (700)
Balance, shares at Dec. 31, 2017		156,675,000
Common stock issued under equity compensation plan, net of shares withheld for taxes	(130)	$ 1	(131)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares		114,000
Exercise of options	28		28
Exercise of options, shares		32,000
Share-based compensation	985		985
Net loss	(6,193)			(6,193)
Other comprehensive income (loss)	10				10
Balance at Mar. 31, 2018	28,247	$ 1,568	303,847	(276,478)	(690)
Balance, shares at Mar. 31, 2018		156,821,000
Balance at Dec. 31, 2018	39,001	$ 1,597	314,907	(276,800)	(703)
Balance, shares at Dec. 31, 2018		159,721,000
Issuance of common stock	7,785	$ 23	7,762
Issuance of common stock, shares		2,307,000
Common stock issued under equity compensation plan, net of shares withheld for taxes	(408)	$ 3	(411)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares		288,000
Exercise of options	350	$ 2	348
Exercise of options, shares		212,000
Share-based compensation	1,366		1,366
Cumulative effect of change in accounting principle	116			116
Net loss	(5,539)			(5,539)
Other comprehensive income (loss)	(3)				(3)
Balance at Mar. 31, 2019	$ 42,668	$ 1,625	$ 323,972	$ (282,223)	$ (706)
Balance, shares at Mar. 31, 2019		162,528,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (5,539)	$ (6,193)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,366	985
Depreciation and amortization	678	604
Other	67	63
Changes in operating assets and liabilities:
Accounts receivable	(10,799)	(608)
Inventories	(2,028)	(655)
Prepaid expenses and other assets	(1,364)	250
Contract assets	997	73
Accounts payable	4,137	550
Accrued expenses and other current liabilities	(25)	(99)
Deferred revenue	520	(999)
Net cash used in operating activities	(11,990)	(6,029)
Cash flows from investing activities:
Proceeds from sale of assets		2,750
Purchases of equipment, molds, furniture and fixtures	(391)	(61)
Additions to patent rights		(10)
Net cash (used in) provided by investing activities	(391)	2,679
Cash flows from financing activities:
Proceeds from issuance of common stock, net	7,785
Proceeds from exercise of stock options	350	28
Taxes paid related to net share settlement of equity awards	(408)	(130)
Net cash provided by (used in) financing activities	7,727	(102)
Effect of exchange rate changes on cash		1
Net decrease in cash and cash equivalents	(4,654)	(3,451)
Cash and cash equivalents:
Beginning of period	27,892	26,562
End of period	23,238	23,111
Supplemental disclosure of non-cash investing activities:
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	$ 399	173
Additions to patent rights recorded in accounts payable and accrued expenses		$ 6

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1. Description of Business Antares Pharma, Inc. (“Antares” or the “Company”) is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The Company develops and commercializes, for itself or with partners, novel therapeutic products using its advanced drug delivery technology to enhance existing drug compounds and delivery methods. The Company’s intramuscular and subcutaneous injection technology platforms include the VIBEX ® ® ® The Company developed and commercialized XYOSTED TM TM The Company also markets and sells its proprietary product OTREXUP ® Through its commercialization partner Teva, the Company sells Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults. Sumatriptan Injection USP was launched for commercial sale in June 2016. In collaboration with AMAG, the Company developed a subcutaneous auto injector for use with AMAG’s progestin hormone drug Makena ® ® Through a license, development and supply agreement with Teva, Antares developed and is the exclusive supplier of the device for Teva’s Epinephrine Injection USP, which is indicated for emergency treatment of severe allergic reactions in adults and certain pediatric patients. The product was approved by the FDA in August 2018 and launched for commercial sale in late fourth quarter of 2018. The Company is also developing two multi-dose pen injector products in collaboration with Teva, a combination drug device rescue pen in collaboration with Pfizer, and has other ongoing internal research and development programs.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	2. Basis of Presentation and Significant Accounting Policies The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of the Securities and Exchange Commission's Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying consolidated financial statements and notes thereto should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. Revisions of Prior Period Financial Statements During the preparation of the consolidated financial statements for the year ended December 31, 2018, management revised the presentation of certain regulatory fees between research and development expenses and selling, general and administrative expenses. As a result, the Company also made revisions to its prior period interim consolidated statements of operations as follows: Three months ended March 31, 2018 Research and development, as reported $ 3,320 Research and development, as revised 2,900 Selling, general and administrative, as reported 7,816 Selling, general and administrative, as revised 8,236 These revisions had no impact on the Company’s total operating expenses or net loss. The revisions also had no impact on the consolidated balance sheets or the consolidated statements of comprehensive loss, stockholders’ equity or cash flows. Management evaluated the materiality of the revisions from a quantitative and qualitative perspective and concluded that the revisions are immaterial to the consolidated financial statements. Accounting Pronouncements Recently Adopted The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02 Leases (“Topic 842”) Recent Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production, assembly, warehousing and distribution operations are outsourced to third-parties where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides a reserve for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales, which was $1,088 and $847 at March 31, 2019 and December 31, 2018, respectively. Inventories consist of the following: March 31, December 31, 2019 2018 Inventories: Raw material $ 26 $ 26 Work in process 7,713 7,622 Finished goods 5,639 3,702 $ 13,378 $ 11,350 Equipment, Molds, Furniture, and Fixtures Equipment, molds, furniture, and fixtures are stated at cost, net of accumulated depreciation, and are depreciated using the straight-line method over their estimated useful lives ranging from three to ten years. As of March 31, 2019 and December 31, 2018, the Company’s equipment, molds, furniture and fixtures totaled $15,100 and $14,895, respectively, which is presented net of accumulated depreciation of $8,106 and $7,570 as of March 31, 2019 and December 31, 2018, respectively. Leases The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under non-cancellable operating leases and, beginning in the first quarter of 2019, entered into a master lease arrangement for a fleet of vehicles for use by its sales force. All of the Company’s leasing arrangements are classified as operating leases with remaining lease terms of seven months to three years. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. Each of the Company’s lease arrangements contain renewal options that have not been included in the determination of the lease term, as they are not reasonably certain of exercise. For contracts that contain lease and non-lease components, the Company accounts for both components as a single lease component. Variable lease payments are expensed as incurred. Operating lease costs were $175 for the three months ended March 31, 2019. Cash paid for amounts included in the measurement of operating lease liabilities was $178 for the three months ended March 31, 2019. During the three months ended March 31, 2019, operating lease ROU assets obtained in exchange for operating lease obligations were $1,074. As of March 31, 2019, the weighted average discount rate was approximately 9.5% and the weighted average remaining lease term was 2.7 years. The following table summarizes the Company’s operating lease maturities as of March 31, 2019: Amount 2019 $ 797 2020 515 2021 549 2022 162 Total remaining lease payments 2,023 Less: imputed interest (102 ) Total lease liabilities $ 1,921 Revenue Recognition The Company generates revenue from proprietary and partnered product sales, license and development activities and royalty arrangements. Revenue is recognized when or as the Company transfers control of the promised goods or services to its customers at the transaction price, which is the amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. At inception of each contract, the Company identifies the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company reassesses its reserves for variable consideration at each reporting date and makes adjustments, if necessary, The Company has elected to recognize the cost for freight and shipping activities as fulfilment cost. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenue. Proprietary Product Sales The Company sells its proprietary products OTREXUP ® TM The determination of certain of these reserves and sales allowances require management to make a number of judgements and estimates to reflect the Company’s best estimate of the transaction price and the amount of consideration to which it believes it is ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and expected utilization rates, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. Reserves for prompt payment discounts are recorded as a reduction in accounts receivable. Reserves for returns, rebates and chargebacks, distributor fees and customer co-pay support programs are included within current liabilities in the consolidated balance sheets. Partnered Product Sales The Company is party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which the Company produces and is the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as follows: The Company is the exclusive supplier of the Makena ® All other partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no price protection or right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, if any. For example, the Company sells Sumatriptan Injection USP to Teva at cost and is entitled to receive 50 percent of the net profits from commercial sales made by Teva, payable to the Company within 45 days after the end of the quarter in which the commercial sales are made. The Company recognizes revenue, including the estimated variable consideration it expects to receive for contract margin on future commercial sales, upon shipment of the goods to Teva. The estimated variable consideration is recognized at an amount the Company believes is not subject to significant reversal based on historical experience, and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed. Licensing and Development Revenue The Company has entered into several license, development and supply arrangements with pharmaceutical partners under which the Company grants a license to its device technology and know-how and provides research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, the Company identifies each of the promised goods and services within the contract and the distinct performance obligations at inception, and allocates consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus margin. If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, the Company recognized revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and the Company has a present right to payment. The Company’s typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. The Company records a liability for cash received in advance of performance, which is presented within deferred revenue on the consolidated balance sheet and recognized as revenue when the associated performance obligations have been satisfied. License fees and milestones received in exchange for the grant of a license to the Company’s functional intellectual property (“IP”) such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is not generally distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events, are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved. Royalties The Company earns royalties in connection with licenses granted under license and development arrangements with partners. Royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid single digit to low double digit and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners’ commercial sales occur. The royalties are generally reported and payable to the Company within 45 to 60 days of the end of the period in which the commercial sales are made. The Company bases its estimates of royalties earned on actual sales information from its partners when available or estimated prescription sales from external sources and estimated net selling price. If actual royalties received are different than amounts estimated, the Company would adjust the royalty revenue in the period in which the adjustment becomes known. Remaining Performance Obligations Remaining performance obligations represents the allocation of transaction price of firm orders and development contract deliverables for which work has not been completed or orders fulfilled, and excludes potential purchase orders under ordering-type supply contracts with indefinite delivery or quantity. As of March 31, 2019, the aggregate value of remaining performance obligations, excluding contracts with an original expected length of one year or less, was $4.8 million. The Company expects to recognize revenue on the remaining performance obligations over the next 2.5 years.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Stockholders' Equity	3. Stockholders’ Equity The Company has a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) under which the Company may offer and sell, from time to time and at its sole discretion, shares of its common stock having an aggregate offering price of up to $30.0 million through Cowen as the Company’s sales agent and/or as principal. Cowen may sell the common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act of 1933, as amended (the “Offering”.) The Company pays a commission of 3.0% of the gross sales proceeds of any common stock sold through Cowen under the Sales Agreement. During the three months ended March 31, 2019, the Company sold 2.3 million shares of common stock pursuant to the Offering and Sales Agreement. The sale of common stock resulted in aggregate gross proceeds of $8.1 million, less sales commission and payment of offering costs, resulting in net offering proceeds to the Company of $7.8 million. No sales of common stock were made in the period ended March 31, 2018. The net proceeds are intended to be used for general corporate purposes including, but not limited to, product commercialization, research and development projects, funding of clinical trials, capital expenditures and working capital.

Share Based Compensation

Share Based Compensation	3 Months Ended
	Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share Based Compensation	4 . Share-Based Compensation The Company’s 2008 Equity Compensation Plan, as amended and restated (the “Plan”) allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards. All of the Company’s officers, directors, employees, consultants and advisors are eligible to receive grants under the Plan. The maximum number of shares authorized for issuance under the Plan is 32,200 and the maximum number of shares of stock that may be granted to any one employee for qualified performance-based compensation during a calendar year is 4,000 shares. Options to purchase shares of common stock are granted at exercise prices not less than 100% of fair market value on the dates of grant. The term of each option is ten years and the options typically vest in quarterly installments over a three-year period with a minimum vesting period of one year. As of March 31, 2019, the Plan had approximately 3,148 shares available for grant. Stock option exercises are satisfied through the issuance of new shares. Stock Options The following is a summary of stock option activity under the Plan as of and for the three months ended March 31, 2019: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding at December 31, 2018 14,079 $ 2.19 Granted 20 3.72 Exercised (212 ) 1.65 Cancelled/Forfeited (30 ) 2.95 Outstanding at March 31, 2019 13,857 2.20 6.4 $ 12,048 Exercisable at March 31, 2019 11,025 $ 2.09 5.8 $ 10,853 During the three months ended March 31, 2019, stock option exercises resulted in cash proceeds to the Company of $350 and the issuance of 212 shares of common stock. Stock option exercises resulted in proceeds of $28 and the issuance of 32 shares of common stock in the three months ended March 31, 2018. The Company recognized $908 and $661 of compensation expense related to stock options for the three months ended March 31, 2019 and 2018, respectively. Long Term Incentive Program The Company’s Board of Directors has approved a long-term incentive program (“LTIP”) for the benefit of the Company’s senior executives. Pursuant to the LTIP, the Company’s senior executives have been awarded stock options, restricted stock units (“RSUs”) and performance stock units (“PSUs”) with targeted values based on values granted to similarly situated senior executives in the Company’s peer group. The stock options have a ten-year term, have an exercise price equal to the closing price of the Company’s common stock on the date of grant, vest in quarterly installments over three years, were otherwise granted on the same standard terms and conditions as other stock options granted pursuant to the Plan and are included in the stock options table above. The RSUs vest in three equal annual installments. The PSU awards made to senior executives vest and convert into shares of the Company’s common stock based on the Company’s attainment of certain performance goals as established by the Company’s Board of Directors over a performance period, which is typically three years. The non-vested PSU awards and RSU awards granted under the long-term incentive program are summarized in the following table: Performance Stock Units Restricted Stock Units Number of Shares Weighted Average Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2018 1,842 $ 2.41 1,226 $ 2.44 Granted — — — — Vested/settled (415 ) 1.18 — — Forfeited/expired (178 ) 1.12 — — Outstanding at March 31, 2019 1,249 $ 3.01 1,226 $ 2.44 In connection with PSU awards, the Company recognized compensation expense of $127 and $79 for the three months ended March 31, 2019 and 2018, respectively. Compensation expense recognized in connection with RSU awards was $331 and $245 for the three months ended March 31, 2019 and 2018, respectively. The LTIP awards that vested during the three months ended March 31, 2019 and 2018 were net-share settled such that the Company withheld shares with a value equivalent to the employees’ tax obligations for applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The Company withheld 127 and 59 shares during the three months ended March 31, 2019 and 2018, respectively, to satisfy tax obligations, which was determined based on the fair value of the shares on their vesting date equal to the Company’s closing stock price on such date. Total payments for the employees’ tax obligations to the taxing authorities were $408 and $130 for the three months ended March 31, 2019 and 2018, respectively, and are reflected as a cash outflow from financing activities within the consolidated statements of cash flows. Net-share settlements have the effect of share repurchases by the Company as they reduce the number of shares that would have otherwise been issued as a result of the vesting.

Revenues, Significant Customers

Revenues, Significant Customers and Concentrations of Risk	3 Months Ended
	Mar. 31, 2019
Revenue From Contract With Customer [Abstract]
Revenues, Significant Customers and Concentrations of Risk	5 . Revenues, Significant Customers and Concentrations of Risk The following table presents the Company’s revenue on a disaggregated basis by types of goods and services and major product lines: Three months ended March 31, 2019 2018 Proprietary product sales $ 4,771 $ 3,971 Partnered product sales 13,529 6,978 Total product revenue 18,300 10,949 Licensing and development revenue 915 1,285 Royalties 4,071 469 Total revenue $ 23,286 $ 12,703 Revenues disaggregated by customer location are as follows: Three Months Ended March 31, 2019 2018 United States of America $ 21,185 $ 11,201 Europe 2,090 1,419 Other 11 83 $ 23,286 $ 12,703 Significant customers from which the Company derived 10% or more of its total revenue in any of the periods presented are as follows: Three Months Ended March 31, 2019 2018 Teva $ 10,611 $ 4,167 AMAG 4,592 2,834 McKesson 1,247 1,843 AmerisourceBergen 1,581 1,423 Ferring 3,096 1,474

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Net Loss Per Share	6 . Net Loss Per Share Basic loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per common share reflects the potential dilution from the exercise or conversion of securities into common stock. Potentially dilutive stock options and other share-based awards excluded from dilutive loss per share because their effect was anti-dilutive totaled 16,332 and 14,481 at March 31, 2019 and 2018, respectively.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Pending Litigation On October 23, 2017, Randy Smith filed a complaint in the District of New Jersey, captioned Randy Smith, Individually and on Behalf of All Others Similarly Situated v. Antares Pharma, Inc., Robert F. Apple and Fred M. Powell Smith TM TM On January 12, 2018, a stockholder of the Company filed a derivative civil action, captioned Chiru Mackert, derivatively on behalf of Antares Pharma, Inc., v. Robert F. Apple, et al. Mackert Vikram Rao, Derivatively on Behalf of Antares Pharma, Inc. v. Robert F. Apple, et al. Rao Smith Smith On January 17, 2018, a stockholder of the Company filed a derivative civil action, captioned Robert Clark, Derivatively on Behalf of Antares Pharma, Inc. v. Robert F. Apple, et al. Clark Smith Clark Smith

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Revisions of Prior Period Financial Statements	Revisions of Prior Period Financial Statements During the preparation of the consolidated financial statements for the year ended December 31, 2018, management revised the presentation of certain regulatory fees between research and development expenses and selling, general and administrative expenses. As a result, the Company also made revisions to its prior period interim consolidated statements of operations as follows: Three months ended March 31, 2018 Research and development, as reported $ 3,320 Research and development, as revised 2,900 Selling, general and administrative, as reported 7,816 Selling, general and administrative, as revised 8,236 These revisions had no impact on the Company’s total operating expenses or net loss. The revisions also had no impact on the consolidated balance sheets or the consolidated statements of comprehensive loss, stockholders’ equity or cash flows. Management evaluated the materiality of the revisions from a quantitative and qualitative perspective and concluded that the revisions are immaterial to the consolidated financial statements.
Recent Accounting Pronouncements	Accounting Pronouncements Recently Adopted The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02 Leases (“Topic 842”) Recent Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production, assembly, warehousing and distribution operations are outsourced to third-parties where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides a reserve for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales, which was $1,088 and $847 at March 31, 2019 and December 31, 2018, respectively. Inventories consist of the following: March 31, December 31, 2019 2018 Inventories: Raw material $ 26 $ 26 Work in process 7,713 7,622 Finished goods 5,639 3,702 $ 13,378 $ 11,350
Equipment, Molds, Furniture, and Fixtures	Equipment, Molds, Furniture, and Fixtures
Leases	Leases The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under non-cancellable operating leases and, beginning in the first quarter of 2019, entered into a master lease arrangement for a fleet of vehicles for use by its sales force. All of the Company’s leasing arrangements are classified as operating leases with remaining lease terms of seven months to three years. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. Each of the Company’s lease arrangements contain renewal options that have not been included in the determination of the lease term, as they are not reasonably certain of exercise. For contracts that contain lease and non-lease components, the Company accounts for both components as a single lease component. Variable lease payments are expensed as incurred. Operating lease costs were $175 for the three months ended March 31, 2019. Cash paid for amounts included in the measurement of operating lease liabilities was $178 for the three months ended March 31, 2019. During the three months ended March 31, 2019, operating lease ROU assets obtained in exchange for operating lease obligations were $1,074. As of March 31, 2019, the weighted average discount rate was approximately 9.5% and the weighted average remaining lease term was 2.7 years. The following table summarizes the Company’s operating lease maturities as of March 31, 2019: Amount 2019 $ 797 2020 515 2021 549 2022 162 Total remaining lease payments 2,023 Less: imputed interest (102 ) Total lease liabilities $ 1,921
Revenue Recognition	Revenue Recognition The Company generates revenue from proprietary and partnered product sales, license and development activities and royalty arrangements. Revenue is recognized when or as the Company transfers control of the promised goods or services to its customers at the transaction price, which is the amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. At inception of each contract, the Company identifies the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company reassesses its reserves for variable consideration at each reporting date and makes adjustments, if necessary, The Company has elected to recognize the cost for freight and shipping activities as fulfilment cost. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenue. Proprietary Product Sales The Company sells its proprietary products OTREXUP ® TM The determination of certain of these reserves and sales allowances require management to make a number of judgements and estimates to reflect the Company’s best estimate of the transaction price and the amount of consideration to which it believes it is ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and expected utilization rates, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. Reserves for prompt payment discounts are recorded as a reduction in accounts receivable. Reserves for returns, rebates and chargebacks, distributor fees and customer co-pay support programs are included within current liabilities in the consolidated balance sheets. Partnered Product Sales The Company is party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which the Company produces and is the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as follows: The Company is the exclusive supplier of the Makena ® All other partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no price protection or right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, if any. For example, the Company sells Sumatriptan Injection USP to Teva at cost and is entitled to receive 50 percent of the net profits from commercial sales made by Teva, payable to the Company within 45 days after the end of the quarter in which the commercial sales are made. The Company recognizes revenue, including the estimated variable consideration it expects to receive for contract margin on future commercial sales, upon shipment of the goods to Teva. The estimated variable consideration is recognized at an amount the Company believes is not subject to significant reversal based on historical experience, and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed. Licensing and Development Revenue The Company has entered into several license, development and supply arrangements with pharmaceutical partners under which the Company grants a license to its device technology and know-how and provides research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, the Company identifies each of the promised goods and services within the contract and the distinct performance obligations at inception, and allocates consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus margin. If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, the Company recognized revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and the Company has a present right to payment. The Company’s typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. The Company records a liability for cash received in advance of performance, which is presented within deferred revenue on the consolidated balance sheet and recognized as revenue when the associated performance obligations have been satisfied. License fees and milestones received in exchange for the grant of a license to the Company’s functional intellectual property (“IP”) such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is not generally distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events, are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved. Royalties The Company earns royalties in connection with licenses granted under license and development arrangements with partners. Royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid single digit to low double digit and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners’ commercial sales occur. The royalties are generally reported and payable to the Company within 45 to 60 days of the end of the period in which the commercial sales are made. The Company bases its estimates of royalties earned on actual sales information from its partners when available or estimated prescription sales from external sources and estimated net selling price. If actual royalties received are different than amounts estimated, the Company would adjust the royalty revenue in the period in which the adjustment becomes known. Remaining Performance Obligations Remaining performance obligations represents the allocation of transaction price of firm orders and development contract deliverables for which work has not been completed or orders fulfilled, and excludes potential purchase orders under ordering-type supply contracts with indefinite delivery or quantity. As of March 31, 2019, the aggregate value of remaining performance obligations, excluding contracts with an original expected length of one year or less, was $4.8 million. The Company expects to recognize revenue on the remaining performance obligations over the next 2.5 years.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Summary of Revisions to Prior Period Interim Consolidated Statements of Operations	As a result, the Company also made revisions to its prior period interim consolidated statements of operations as follows: Three months ended March 31, 2018 Research and development, as reported $ 3,320 Research and development, as revised 2,900 Selling, general and administrative, as reported 7,816 Selling, general and administrative, as revised 8,236
Inventories	Inventories consist of the following: March 31, December 31, 2019 2018 Inventories: Raw material $ 26 $ 26 Work in process 7,713 7,622 Finished goods 5,639 3,702 $ 13,378 $ 11,350
Summary of Operating Lease Maturities	The following table summarizes the Company’s operating lease maturities as of March 31, 2019: Amount 2019 $ 797 2020 515 2021 549 2022 162 Total remaining lease payments 2,023 Less: imputed interest (102 ) Total lease liabilities $ 1,921

Share Based Compensation (Table

Share Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	The following is a summary of stock option activity under the Plan as of and for the three months ended March 31, 2019: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding at December 31, 2018 14,079 $ 2.19 Granted 20 3.72 Exercised (212 ) 1.65 Cancelled/Forfeited (30 ) 2.95 Outstanding at March 31, 2019 13,857 2.20 6.4 $ 12,048 Exercisable at March 31, 2019 11,025 $ 2.09 5.8 $ 10,853
Schedule of Non-vested Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program	The non-vested PSU awards and RSU awards granted under the long-term incentive program are summarized in the following table: Performance Stock Units Restricted Stock Units Number of Shares Weighted Average Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2018 1,842 $ 2.41 1,226 $ 2.44 Granted — — — — Vested/settled (415 ) 1.18 — — Forfeited/expired (178 ) 1.12 — — Outstanding at March 31, 2019 1,249 $ 3.01 1,226 $ 2.44

Revenues, Significant Custome_2

Revenues, Significant Customers and Concentrations of Risk (Tables)	3 Months Ended
	Mar. 31, 2019
Revenue From Contract With Customer [Abstract]
Summary of Revenues Disaggregated by Types of Goods and Services and Major Product and Customer Location	The following table presents the Company’s revenue on a disaggregated basis by types of goods and services and major product lines: Three months ended March 31, 2019 2018 Proprietary product sales $ 4,771 $ 3,971 Partnered product sales 13,529 6,978 Total product revenue 18,300 10,949 Licensing and development revenue 915 1,285 Royalties 4,071 469 Total revenue $ 23,286 $ 12,703 Revenues disaggregated by customer location are as follows: Three Months Ended March 31, 2019 2018 United States of America $ 21,185 $ 11,201 Europe 2,090 1,419 Other 11 83 $ 23,286 $ 12,703
Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue	Significant customers from which the Company derived 10% or more of its total revenue in any of the periods presented are as follows: Three Months Ended March 31, 2019 2018 Teva $ 10,611 $ 4,167 AMAG 4,592 2,834 McKesson 1,247 1,843 AmerisourceBergen 1,581 1,423 Ferring 3,096 1,474

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Summary of Revisions to Prior Period Interim Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Research and development	$ 2,387	$ 2,900
Selling, general and administrative	$ 14,935	8,236
As Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Research and development		3,320
Selling, general and administrative		$ 7,816

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018	Dec. 31, 2017
Summary of Significant Accounting Policies [Line Items]
Right-of-use assets	$ 1,910
Lease liability	1,921
Accumulated deficit	(282,223)		$ (276,800)
Inventory reserve	1,088			$ 847
Equipment, molds, furniture and fixtures, net	15,100		14,895
Accumulated depreciation	8,106		$ 7,570
Operating lease costs	175
Cash paid for operating lease liabilities	178
Operating lease ROU assets obtained in exchange for operating lease obligations	$ 1,074
Weighted average discount rate	9.50%
Weighted average remaining lease term	2 years 8 months 12 days
Remaining performance obligations	$ 4,800
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation	The Company expects to recognize revenue on the remaining performance obligations over the next 2.5 years
Teva [Member]
Summary of Significant Accounting Policies [Line Items]
Future net profits from commercial sales percent	50.00%
Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	3 years
Remaining lease term	7 months
Royalty payment period	45 days
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	10 years
Remaining lease term	3 years
Royalty payment period	60 days
ASU 2016-02 [Member]
Summary of Significant Accounting Policies [Line Items]
Right-of-use assets		$ 1,000
Lease liability		1,000
Accumulated deficit		$ (100)

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies - Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw material	$ 26	$ 26
Work in process	7,713	7,622
Finished goods	5,639	3,702
Inventory, Total	$ 13,378	$ 11,350

Basis of Presentation and Sig_7

Basis of Presentation and Significant Accounting Policies - Summary of Operating Lease Maturities (Detail) $ in Thousands	Mar. 31, 2019USD ($)
Operating Lease Liabilities Payments Due [Abstract]
2019	$ 797
2020	515
2021	549
2022	162
Total remaining lease payments	2,023
Less: imputed interest	(102)
Total lease liabilities	$ 1,921

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Aug. 31, 2017	Mar. 31, 2019	Mar. 31, 2018
Stockholders Equity [Line Items]
Aggregate offering price of common stock		$ 7,785,000
Proceeds from sale of common stock		$ 7,785,000
Sales Agreement [Member] | Cowen and Company, LLC [Member]
Stockholders Equity [Line Items]
Percentage of commission on proceeds from gross sales of common stock	3.00%
Sales Agreement [Member] | Cowen and Company, LLC [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Aggregate offering price of common stock	$ 30,000,000
Offering and Sales Agreement [Member]
Stockholders Equity [Line Items]
Issuance of common stock, shares		2,300,000
Gross proceeds from sale of common stock		$ 8,100,000
Proceeds from sale of common stock		$ 7,800,000	$ 0

Share Based Compensation - Addi

Share Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from the issuance of stock options	$ 350	$ 28
Shares withheld to meet employees' statutory income tax obligation	127,000	59,000
Payments for the employees' statutory income tax obligation	$ 408	$ 130
Employees Tax Obligations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments for the employees' statutory income tax obligation	$ 408	130
Amended and Restated 2008 Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized	32,200,000
Maximum number of shares of stock granted to one participant	4,000,000
Minimum percentage of exercise price	100.00%
Shares available for grant under the plan	3,148,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from the issuance of stock options	$ 350	$ 28
Exercise of options, shares	212,000	32,000
Recognized compensation cost related to shares of stock granted	$ 908	$ 661
Stock Options [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of options granted	10 years
Vesting period	3 years
Stock Options [Member] | Amended and Restated 2008 Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of options granted	10 years
Vesting period	3 years
Stock Options [Member] | Minimum [Member] | Amended and Restated 2008 Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Restricted Stock Units [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Recognized compensation cost related to shares of stock granted	$ 331	245
Performance Stock Units [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Recognized compensation cost related to shares of stock granted	$ 127	$ 79

Share Based Compensation - Summ

Share Based Compensation - Summary of Stock Option Activity (Detail) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Stockholders Equity Note [Abstract]
Number of Shares Outstanding, Beginning Balance | shares	14,079,000
Number of Shares Granted | shares	20,000
Number of Shares Exercised | shares	(212,000)
Number of Shares Cancelled/Forfeited | shares	(30,000)
Number of Shares Outstanding, Ending Balance | shares	13,857,000
Number of Shares Exercisable, Ending Balance | shares	11,025,000
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 2.19
Weighted Average Exercise Price Granted | $ / shares	3.72
Weighted Average Exercise Price Exercised | $ / shares	1.65
Weighted Average Exercise Price Cancelled/Forfeited | $ / shares	2.95
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	2.20
Weighted Average Exercise Price Exercisable, Ending Balance | $ / shares	$ 2.09
Weighted Average Remaining Contractual Term (Years) Outstanding, Ending Balance	6 years 4 months 24 days
Weighted Average Remaining Contractual Term (Years) Exercisable, Ending Balance	5 years 9 months 18 days
Aggregate Intrinsic Value Outstanding, Ending Balance | $	$ 12,048
Aggregate Intrinsic Value Exercisable, Ending Balance | $	$ 10,853

Share Based Compensation - Sche

Share Based Compensation - Schedule of Non-vested Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program (Detail)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance | shares	1,842,000
Number of Shares, Vested/settled | shares	(415,000)
Number of Shares, Forfeited/expired | shares	(178,000)
Number of Shares, Ending Balance | shares	1,249,000
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 2.41
Weighted Average Grant Date Fair Value, Vested/settled | $ / shares	1.18
Weighted Average Grant Date Fair Value, Forfeited/expired | $ / shares	1.12
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 3.01
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance | shares	1,226,000
Number of Shares, Ending Balance | shares	1,226,000
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 2.44
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 2.44

Revenues, Significant Custome_3

Revenues, Significant Customers and Concentrations of Risk - Summary of Revenue Disaggregated by Types of Goods and Services and Major Product (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation Of Revenue [Line Items]
Total revenue	$ 23,286	$ 12,703
Total Product Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	18,300	10,949
Total Product Revenue [Member] | Proprietary Product [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	4,771	3,971
Total Product Revenue [Member] | Partnered Product [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	13,529	6,978
Licensing and Development Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	915	1,285
Royalties [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 4,071	$ 469

Revenues, Significant Custome_4

Revenues, Significant Customers and Concentrations of Risk - Summary of Revenues Disaggregated by Customer Location (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation Of Revenue [Line Items]
Total revenues	$ 23,286	$ 12,703
United States of America [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	21,185	11,201
Europe [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	2,090	1,419
Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	$ 11	$ 83

Revenues, Significant Custome_5

Revenues, Significant Customers and Concentrations of Risk - Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Concentration Risk [Line Items]
Total revenues	$ 23,286	$ 12,703
Teva [Member]
Concentration Risk [Line Items]
Total revenues	10,611	4,167
AMAG [Member]
Concentration Risk [Line Items]
Total revenues	4,592	2,834
McKesson [Member]
Concentration Risk [Line Items]
Total revenues	1,247	1,843
AmerisourceBergen [Member]
Concentration Risk [Line Items]
Total revenues	1,581	1,423
Ferring [Member]
Concentration Risk [Line Items]
Total revenues	$ 3,096	$ 1,474

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Earnings Per Share [Abstract]
Potentially dilutive stock options and other share-based awards excluded from dilutive loss per share	16,332,000	14,481,000